Drug Trial Radar · NCT02311894
A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency
Last checked: Nov 20, 2026Latest source record: Jan 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
82
Actual
Start
Mar 31, 2015
Primary completion
Nov 8, 2017
Study completion Nov 8, 2017
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Dec 9, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 3 years, up to 14 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase IV, multicenter, open-label, single-arm study of somatropin (rDNA origin) (Nutropin AQ v1.1) in pre-pubertal children with growth hormone deficiency (GHD) naïve to prior recombinant human growth hormone (rhGH) treatment. The study is designed to characterize the immunogenicity profile of somatropin (rDNA origin) injection when administered daily subcutaneously for 12 months. The clinical impact of immunogenicity will also be assessed.
Conditions
- Growth Hormone Deficiency
Interventions
SomatropinDrug
Somatropin will be administered as SC injections at a dose of up to 0.043 mg/kg/day. The dose may be adjusted for a change in body weight of at least (plus \[+\]/minus \[-\]) 2 kilograms (kg) from baseline at the Month 6 study visit or for a change in insulin-growth factor-1 (IGF-1), as per investigator assessment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Develop Anti-GH Antibodies After Treatment With Nutropin AQ v1.1Time frame: Baseline up to 1 year
Locations
33 sites in 1 country. Site status is shown where the registry gives one.
Arkansas Children's Hospital Research Institute
Little Rock, Arkansas
Children'S Hospital of Orange County
Orange, California
Center of Excellence in Diabetes & Endocrinology
Sacramento, California
San Diego Medical Group; Pediatric Endocrinology
San Diego, California
Rocky Mountain Pediatric Endocrinology, PC
Centennial, Colorado
Pediatric Endocrine Associates
Greenwood Village, Colorado
Nemours Children's Clinic - of the Nemours Foundation
Jacksonville, Florida
Miami Children's Hospital
Miami, Florida
Nemours Childrens Clinic
Orlando, Florida
The Pediatric Endocrine Office of Larry C. Deeb
Tallahassee, Florida
Pediatric Endrocine Assoc
Tampa, Florida
USF Diabetes Center
Tampa, Florida
Emory Children's Center
Atlanta, Georgia
University of Louisville
Louisville, Kentucky
Barry J Reiner, MD, LLC
Baltimore, Maryland
Boston Childrens Hospital
Boston, Massachusetts
Baystate Endocrinology and Diabetes; Baystate Children's Specialty Center, Pediatric Endocrinology
Springfield, Massachusetts
University of Michigan
Ann Arbor, Michigan
University of Minnesota Childrens' Hospital
Minneapolis, Minnesota
Children's Healthcare d.b.a Children's Hospitals and Clinics of Minnesota
Saint Paul, Minnesota
Children's Mercy Hospitals & Clinics; Pulmonology
Kansas City, Missouri
Hackensack University Medical Center PARTNER
Hackensack, New Jersey
New York Presbyterian Hospital
New York, New York
UNC General Pediatrics Clinic
Chapel Hill, North Carolina
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma
Oregon Health and Science University
Portland, Oregon
Milton S Hershey Ped Sub Spclt
Hershey, Pennsylvania
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
Medical University of South Carolina; MUSC Pediatric Endocrinology
Charleston, South Carolina
Endocrine Associates of Dallas
Dallas, Texas
Cook Children's Hospital
Fort Worth, Texas
MultiCare Health System Institute for Research and Innovation
Tacoma, Washington
MultiCare Institute for Research and Innovation
Tacoma, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.